AstraZeneca's Seroquel XR receives complete response letter for GAD
This article was originally published in Scrip
The US FDA has issued AstraZeneca with a complete response letter for its antipsychotic Seroquel XR (quetiapine fumarate) extended-release tablets for the treatment of generalised anxiety disorder (GAD) in adults.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.